G. Lawton – författare

The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are ''druggable'', is the best starting point for improved productivity.The seven chapters of this volume describe recent progress towards drugs acting at a range of ''druggable'' targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapters cover G-protein coupled receptors, which has historically perhaps been the most fruitful area for medicinal chemists.*Presents the latest research in the field of drug discovery *Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a ''quality lead'', where these ''quality leads'' come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.*Presents the latest research in the field of drug discovery *Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

Presents the latest research in the field of drug discovery Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry Available as an online resource via ScienceDirect

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

Presents the latest research in the field of drug discovery Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry Available as an online resource via ScienceDirect

The Progress in Medicinal Chemistry series spans a wide range of topics of interest to the drug discovery community. This particular volume touches upon the following:* The Herg ion channel * Fluorescence-based high throughput assay * Aprepitant and neurokinin receptors * Muscarinic receptor targets * Gene activation pathways * Malaria and antimalarial drugs * HIV virus mutation and new therapeuticsProgress in Medicinal Chemistry is available online on ScienceDirect - full-text online of volumes 41 onwards. Elsevier book series on ScienceDirect gives multiple users throughout an institution simultaneous online access to an important compliment to primary research. Digital delivery ensures users reliable, 24-hour access to the latest peer-reviewed content. The Elsevier book series are compiled and written by the most highly regarded authors in their fields and are selected from across the globe using Elsevier's extensive researcher network. For more information about the Elsevier Book Series on ScienceDirect Program, please visit:http://www.info.sciencedirect.com/bookseries/*Presents the latest research in the field of drug discovery*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry*Available as an online resource via ScienceDirect

The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are 'druggable', is the best starting point for improved productivity.The seven chapters of this volume describe recent progress towards drugs acting at a range of 'druggable' targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapters cover G-protein coupled receptors, which has historically perhaps been the most fruitful area for medicinal chemists.*Presents the latest research in the field of drug discovery *Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a 'quality lead', where these 'quality leads' come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.*Presents the latest research in the field of drug discovery *Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, 'validation' of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging: * HIV integrase (discovery of the first-in-class inhibitor drug raltegravir)* 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation)* Nicotinic a7 choline receptor (agonists and positive allosteric modulators). * Bradykinin receptor (new approach to pain therapy)* Histone deacetylase (new drugs for cancer)* 5-HT2c receptor modulators (various CNS indications)Presents the latest research in the field of drug discoveryPublishes on an annual basis to bring you the most innovative updates in medicinal chemistryAvailable as an online resource via ScienceDirect

This volume provides reviews of six topics demonstrating the breadth of the field and recent successes in medicinal chemistry. Each of the first five chapters takes an important biochemical target as its theme and provides an insight into current progress in drug design. The last chapter focuses on the vital subject of pharmacokinetics and the great strides that have been made in this discipline during the past decade. All chapters provide an insight into the skills required of the modern medicinal chemist, in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.Presents the latest research in the field of drug discoveryPublishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistryAvailable as an online resource via ScienceDirect

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems. Presents the latest research in the field of drug discovery Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry Available as an online resource via ScienceDirect

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems. Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems, including g-secretase modulators, P2X7 antagonists as therapeutic agents for CNS disorders, N-type calcium channel modulators for the treatment of pain, and more. Extended timely reviews of topics in medicinal chemistry Targets and technologies relevant to the discovery of tomorrow's drugs Analyses of successful drug discovery programmes

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume includes chapters covering recent advances in cancer therapeutics, fluorine in medicinal chemistry, a perspective on the next generation of antibacterial agents derived by manipulation of natural products, a new era for Chagas Disease drug discovery? and imaging in drug development.

Extended timely reviews of topics in medicinal chemistry Targets and technologies relevant to the discovery of tomorrow's drugs Analyses of successful drug discovery programmes